Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development, and commercialization of pharmaceutical products aimed at treating various human diseases, including conditions related to immunology, metabolism, cardiology, and ophthalmology. The company has several drug candidates in its pipeline, including LX1031 for irritable bowel syndrome, LX4211 for type 2 diabetes, LX2931 for rheumatoid arthritis, and LX1032 for symptoms associated with carcinoid syndrome, all of which have completed Phase II clinical trials. Additionally, it is developing LX7101 in preclinical stages for glaucoma treatment. Lexicon's portfolio also includes LX9211 for neuropathic pain and sotagliflozin for heart failure and type 1 diabetes. The company collaborates with prominent pharmaceutical partners such as Bristol-Myers Squibb, Genentech, and Takeda, and engages in various drug discovery and development alliances to enhance its research capabilities.